Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Integrated microfluidic platform for the capture and identification of circulating tumor cells using dielectrophoresis and image recognition.

Created on 21 Oct 2026

Authors

Min-Sheng Hung, Sheng-Ze Qiu, Yu-Cheng Wu

Published in

Bioanalysis. Pages 1-10. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Circulating tumor cells (CTCs), which detach from primary tumors and enter the peripheral blood, serve as biomarkers for monitoring a patient's status following cancer therapy.
In this study, we developed a microfluidic platform integrating dielectrophoresis and image recognition for the capture and detection of CTCs from blood sample. Experimental parameters included applied electric field strengths ranging from 12.5 to 32.5 × 104 V/m (at 1 MHz) and sample flow rates of 6.25-31.25 mm/min. Fluorescent antibodies were employed to label captured CTCs for real-time detection. Furthermore, a detection software utilizing OpenCV was developed to label CTCs through image processing. The identification performance of the self-developed software was evaluated and compared with machine learning algorithms.
Results demonstrated that the optimal CTC separation efficiency of 78 ± 2% was achieved at an electric field of 25 × 104 V/m and a flow rate of 18.75 mm/min. While the self-developed software achieved a lower recall than the YOLOv8 model (85 ± 4% vs. 92 ± 2%), its precision matched that of YOLOv8 (90 ± 3% vs. 89 ± 4%).

PMID:
42902582
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement